In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amanda Micklus

Principal Analyst, Datamonitor Healthcare

Connecticut, US
Amanda has been tracking corporate strategy and business development activities in the biopharma and medtech industries for more than 10 years. She is a principal analyst with Informa’s Datamonitor Healthcare where she researches and analyzes trends in corporate strategy and dealmaking, and compiles reports for clients. Amanda also writes trends pieces for Informa’s IN VIVO and START-UP publications, and contributes to Informa’s Strategic Transactions deals database, researching and writing analyses on individual biopharma and medtech transactions. Before joining Informa, Amanda spent five years at Purdue Pharma, working as a market research analyst and information searcher. She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library & Information Science from Long Island University.
Advertisement
Set Alert for Articles By Amanda Micklus

Latest From Amanda Micklus

Deals In Depth: August 2017

Dermira aims to develop Roche's discontinued asthma antibody lebrikizumab in atopic dermatitis, in a deal worth $1.4 billion; Gilead entered CAR-T race with $11.9 billion buy of Kite Pharma. Biopharma funding was way up thanks to a $1.1 billion fundraise by Roivant Sciences.

Deals Market Intelligence

CRISPR In Brief

CRISPR/Cas9 gene editing is fast, efficient and specific. How does it work?

BioPharmaceutical

CRISPR/Cas9 Patent Battle: What's Happened, What's Next?

With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.

Regenerative Medicine Intellectual Property

Deals In Depth: July 2017

AstraZeneca and Merck signed a broad targeted therapy and immuno-oncology alliance worth $8.5 billion; Japanese pharma Mitsubishi Tanabe boosted its neuroscience assets with the acquisition of NeuroDerm. Biopharma financing decreased from June, while device funding went up.

Deals Market Intelligence

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Biopharma Quarterly Deal-Making Statistics, Q2 2017

Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.

BioPharmaceutical Deals
See All
Advertisement
UsernamePublicRestriction

Register